Abstract

BackgroundIn Sri Lanka pertussis continues to circulate in the community and cases among adolescents and adults have been reported despite 95% coverage of the four dose pertussis vaccination during early childhood. Waning of immunity following natural infection or immunization may contribute to the persistent circulation. An adolescent booster dose is not included in the national immunization schedule of Sri Lanka, although this is routine practice in many countries. Therefore information on immunity to pertussis in the adolescent group is needed prior to considering vaccination schedule changes.MethodsThe quantitative determination of specific Immunoglobulin G antibodies to Bordetella pertussis toxin was done using a commercially available validated ELISA method. The antibody values were categorized into groups according to the interpretive criteria provided by the manufacturer. The values were <55 IU/mL, negative; 55–<60 IU/mL, borderline; 60–125 IU/mL, positive; >125, strongly positive respectively. Sera of 385 asymptomatic individuals aged 4 to 24 years admitted to surgical units of Lady Ridgeway Hospital, Colombo and Colombo South Teaching Hospital were used for the study. Mann-Whitney U and Kruskal-Wallis tests were used in analysis of results and p ≤0.05 was considered as statistically significant. Details of epidemiological variables were collected using a questionnaire and correlation with significant levels of pertussis antibodies was determined.ResultsMedian age of the study population was 12 years with 212 (55.1%) females. The median anti PT antibody level was 3.31 IU/mL and 352 (91%) had anti PT levels ≤55 IU/mL. Median of anti PT levels were 3.18 IU/mL for 4–7 years, 1.43 IU/mL (IQR 0.336–6.27) for 8–11 years, 4.28 IU/mL (IQR 0.978–13.39) for 12–15 years, 6.14 IU/mL for 16–19 years and 4.89 IU/mL for 20–24 years and the differences were statistically significant (p = 0.000). Females (p < 0.003) and those having a sibling aged ≥12 years (p = 0.017) had significantly higher anti PT levels.ConclusionsThe majority of the study population, especially 8 to 11 year age group had low anti PT IgG levels. The higher antibody titers in the 12–15 year age group seem to indicate infection in early adolescence. A booster dose of acellular pertussis vaccine need to be considered.

Highlights

  • In Sri Lanka pertussis continues to circulate in the community and cases among adolescents and adults have been reported despite 95% coverage of the four dose pertussis vaccination during early childhood

  • A study unit was defined as a previously healthy individual aged 4–24 years admitted for surgical or trauma care at the Colombo South Teaching Hospital or Lady Ridgeway Hospital or Children who had received the DTwP immunization according to the National Immunization Proramme (NIP) of Sri Lanka

  • Anti pertussis toxin (PT) antibody titers in the whole study population The anti PT antibody levels of the study sample ranged from 0.0153 IU/mL to 149.76 IU/mL and the median value was 3.3108 IU/mL (IQR 0.73–15.12)

Read more

Summary

Introduction

In Sri Lanka pertussis continues to circulate in the community and cases among adolescents and adults have been reported despite 95% coverage of the four dose pertussis vaccination during early childhood. An adolescent booster dose is not included in the national immunization schedule of Sri Lanka, this is routine practice in many countries. Newborns acquire antibodies passively from mothers, most infants are not protected during the first few months of life [4] They are susceptible to life-threatening disease with a high incidence of deaths in the first 6 months of life [4]. Pertussis continues to circulate in the communities and estimates from WHO suggest that in 2008 about 16 million cases of pertussis occurred worldwide, 95% of which were reported in developing countries [7]. Pertussis remains a poorly controlled vaccine preventable diseases in the world

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call